Pnina Fishman
Laboratory of Clinical and Tumor Immunology
The Felsenstein Medical Research Center
Tel Aviv University
Sackler Faculty of Medicine
Israel
Name/email consistency: high
- Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Fishman, P., Bar-Yehuda, S., Ardon, E., Rath-Wolfson, L., Barrer, F., Ochaion, A., Madi, L. Anticancer Res. (2003)
- Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Fishman, P., Madi, L., Bar-Yehuda, S., Barer, F., Del Valle, L., Khalili, K. Oncogene (2002)
- A3 adenosine receptor as a target for cancer therapy. Fishman, P., Bar-Yehuda, S., Madi, L., Cohn, I. Anticancer. Drugs (2002)
- The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Fishman, P., Bar-Yehuda, S., Barer, F., Madi, L., Multani, A.S., Pathak, S. Exp. Cell Res. (2001)